Disease modifying anti-osteoarthritis drugs (DMOADs) - Chondroitin Sulfate and Glucosamine
Osteoarthritis is one of the types of joint illness causing severe joint pain and stiffness in the affected area. In the coming years, this disabling menace is expected to rise and the disease modifying osteoarthritis drugs (DMOADs) would be highly desirable supplements to symptomatic relief and structure reconstruction as they may obstruct the disease process.
Some of the promising results on the metabolism of various cells involved in osteoarthritis as well as in animal models and clinical trials has resulted from the chondroitin sulfate and glucosamine. In the recent meta-analyses, the positive effects (pain and functions as well as their structure-modifying capacity ) of these important biological agents, alone or in combination, have been reported in the clinical trials. In spite of that, profits of these bioactive (macro) molecules as DMOADs reported from randomized trials is mismatched. According to the current studies with varying levels of evidence, chondroitin sulfate and glucosamine can modify the disease progression but at the same time there are not absolute certainties on their effectiveness in modifying the itinerary of the ailment.
Hence, here in this research review, emphasis was made to deduce the part of these compounds in the therapeutic drugs beneficial to osteoarthritis patients.